GlassScriptPhysician profile
Sarah E Neill
NPI 1518301514
$4,930.11
in general payments reported to CMS, 2019-2025
35 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $350 · 2021: $486 · 2022: $1,140 · 2023: $795 · 2024: $906 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $693.41 | 2019-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $475.88 | 2021-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.90 | 2019-2024 | Ofev |
| Insmed, INC. | $389.66 | 2022-2025 | Arikayce |
| United Therapeutics Corporation | $384.69 | 2019-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $279.73 | 2021-2024 | Fasenra, Tezspire |
| Genzyme Corporation | $213.06 | 2022-2024 | |
| Electromed, INC. | $207.08 | 2021-2024 | Smartvest |
| Philips North America LLC | $178.91 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Regeneron Healthcare Solutions, INC. | $175.10 | 2022-2025 | Dupixent, Libtayo |
| Merck Sharp & Dohme LLC | $167.69 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Penumbra, INC. | $161.01 | 2022-2023 | Indigo System |
| Jazz Pharmaceuticals INC. | $149.19 | 2019-2022 | |
| Gilead Sciences, INC. | $128.41 | 2021-2024 | |
| Allergan, INC. | $91.34 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $90.57 | 2023-2025 | Tezspire |
| Baxter Healthcare | $84.11 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $77.54 | 2021-2024 | Prolastin-C Liquid |
| Inari Medical, INC. | $71.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.89 | 2022-2023 | Cinqair |
| Takeda Pharmaceuticals U.S.A., INC. | $45.21 | 2022-2025 | Cuvitru |
| Csl Behring | $44.69 | 2022 | |
| Mylan Specialty L.P. | $42.51 | 2022-2023 | Yupelri |
| Livanova USA, INC. | $40.89 | 2022 | |
| Resmed Corp | $37.81 | 2019-2021 | |
| Harmony Biosciences LLC | $27.64 | 2021-2022 | |
| Axsome Therapeutics, INC. | $25.54 | 2024 | Sunosi |
| Chiesi USA, INC. | $23.86 | 2022 | |
| Mallinckrodt Hospital Products INC. | $23.70 | 2023 | Acthar |
| Olympus America INC. | $21.16 | 2025 | |
| Teleflex LLC | $20.27 | 2024 | Arrow |
| Inogen, INC. | $19.66 | 2024 | |
| Pulmonx Corporation | $17.75 | 2021 | |
| Advanced Respiratory, INC | $16.83 | 2021 | |
| Bard Peripheral Vascular, INC. | $15.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Neill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.